1186 related articles for article (PubMed ID: 15698420)
1. Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications.
Wolf G; Ritz E
Kidney Int; 2005 Mar; 67(3):799-812. PubMed ID: 15698420
[TBL] [Abstract][Full Text] [Related]
2. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
3. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
[TBL] [Abstract][Full Text] [Related]
4. [The renin-angiotensin-aldosterone system -- more complex as previously thought].
Wolf G
Med Klin (Munich); 2005 Aug; 100(8):471-7. PubMed ID: 16096728
[TBL] [Abstract][Full Text] [Related]
5. ACE-inhibitor, AT1-receptor-antagonist, or both? A clinical pharmacologist's perspective after publication of the results of ONTARGET.
Schindler C
Ther Adv Cardiovasc Dis; 2008 Aug; 2(4):233-48. PubMed ID: 19124424
[TBL] [Abstract][Full Text] [Related]
6. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T
Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
[TBL] [Abstract][Full Text] [Related]
7. Add-on angiotensin receptor blockade with maximized ACE inhibition.
Agarwal R
Kidney Int; 2001 Jun; 59(6):2282-9. PubMed ID: 11380832
[TBL] [Abstract][Full Text] [Related]
8. The reno-protective effect of the dual blockade of the renin angiotensin system (RAS).
Luno J; Praga M; de Vinuesa SG
Curr Pharm Des; 2005; 11(10):1291-300. PubMed ID: 15853685
[TBL] [Abstract][Full Text] [Related]
9. Recent changes in the landscape of combination RAS blockade.
Epstein BJ; Smith SM; Choksi R
Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1373-84. PubMed ID: 19900020
[TBL] [Abstract][Full Text] [Related]
10. The Remission Clinic approach to halt the progression of kidney disease.
;
J Nephrol; 2011; 24(3):274-81. PubMed ID: 21534237
[TBL] [Abstract][Full Text] [Related]
11. [Blockade of the renin-angiotensin system by a combination of ACE inhibitors and AT1 receptor antagonists].
Azizi M
Rev Prat; 2004 Jun; 54(11):1167-74. PubMed ID: 15496022
[TBL] [Abstract][Full Text] [Related]
12. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?
Vogt L; Kocks MJ; Laverman GD; Navis G
Minerva Med; 2004 Oct; 95(5):395-409. PubMed ID: 15467515
[TBL] [Abstract][Full Text] [Related]
13. Dual blockade of the renin-angiotensin system in the progression of renal disease: the need for more clinical trials.
Fernandez-Juárez G; Barrio V; de Vinuesa SG; Goicoechea M; Praga M; Luño J
J Am Soc Nephrol; 2006 Dec; 17(12 Suppl 3):S250-4. PubMed ID: 17130270
[TBL] [Abstract][Full Text] [Related]
14. Direct renin inhibition in a rat model of chronic allograft injury.
Rusai K; Schmaderer C; Hermans JJ; Lutz J; Heemann U; Baumann M
Transplantation; 2011 Nov; 92(9):999-1004. PubMed ID: 21956196
[TBL] [Abstract][Full Text] [Related]
15. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.
Tylicki L; Rutkowski P; Renke M; Larczyński W; Aleksandrowicz E; Lysiak-Szydlowska W; Rutkowski B
Am J Kidney Dis; 2008 Sep; 52(3):486-93. PubMed ID: 18423812
[TBL] [Abstract][Full Text] [Related]
16. Combination is better than monotherapy with ACE inhibitor or angiotensin receptor antagonist at recommended doses.
Segura J; Praga M; Campo C; Rodicio JL; Ruilope LM
J Renin Angiotensin Aldosterone Syst; 2003 Mar; 4(1):43-7. PubMed ID: 12692753
[TBL] [Abstract][Full Text] [Related]
17. Impact of angiotensin II on the kidney: does an angiotensin II receptor blocker make sense?
Hollenberg NK
Am J Kidney Dis; 2000 Sep; 36(3 Suppl 1):S18-23. PubMed ID: 10986155
[TBL] [Abstract][Full Text] [Related]
18. Renoprotective benefits of RAS inhibition: from ACEI to angiotensin II antagonists.
Taal MW; Brenner BM
Kidney Int; 2000 May; 57(5):1803-17. PubMed ID: 10792600
[TBL] [Abstract][Full Text] [Related]
19. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
20. [Angiotensin II receptor blockers: current status and future prospects].
Corvol P; Plouin PF
Drugs; 2002; 62 Spec No 1():53-64. PubMed ID: 12036389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]